Journals / Acta Medica / 2020 / Cilt: 51 - Sayı: 2

A Comparison of Baseline Clinical Characteristics of Autoimmune Gastritis Patients with and without Type-1 Gastric Carcinoid Tumor

Pages
17–24
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: High serum gastrin but not chromogranine A levels may be useful in deciding which patients should be followed closely in autoimmune gastritis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Autoimmune gastritis is an antibody-mediated autoimmune disease and characterized by gastric parietal cell loss.
📊
Key Findings & Data:Type-1 gastric carcinoid tumor is a disease that mostly develops on the basis of autoimmune gastritis.
💡
Conclusion & Impact:Conclusion: High serum gastrin but not chromogranine A levels may be useful in deciding which patients should be followed closely in autoimmune gastritis.
🔬Design:Research Article
📍Scope:2004 Verileri
⚙️Variables:Domain Parameters

Özet

Objectives: Autoimmune gastritis is an antibody-mediated autoimmune disease and characterized by gastric parietal cell loss. Type-1 gastric carcinoid tumor is a disease that mostly develops on the basis of autoimmune gastritis. The aim of this study is to determine similarities and differences of baseline clinical parameters between these two disorders. Methods: Patients diagnosed as autoimmune gastritis both without gastric carcinoid tumor (n:197) and with gastric carcinoid tumor (n:40) between 2004 and 2015 at Ankara University Faculty of Medicine, Department of Gastroenterology, were included in this analysis. Data of initial signs and symptoms, basal blood count-anemia parameters, laboratory investigations, serum gastrin levels, antiparietal cell antibody status, serological helicobacter pylori markers and serum chromogranine A levels of patients were obtained, and baseline parameters of these disorders were compared Results: Patient groups were similar in age and gender. Hemoglobin, iron, total iron binding capacity, ferritin, vitamin B12 levels, antiparietal cell antibody and helicobacter pylori immunoglobulin G positivity rates and concomitant autoimmune thyroid disease prevalence were also similar. Median gastrin level in patients with autoimmune gastritis and gastric carcinoid tumors was significantly higher compared to the patients with autoimmune gastritis without gastric carcinoid tumors (807 vs. 1307 pg/ml; p:0.006). Receiver Operating Characteristic analysis revealed that a 1000 pg/ml threshold value for serum gastrin level is able to distinguish these two disorders with 65% sensitivity and 65% specificity rates (area under the curve: 0.65;p:0.006). The serum chromogranine A level did not significantly differ between patient groups. Conclusion: High serum gastrin but not chromogranine A levels may be useful in deciding which patients should be followed closely in autoimmune gastritis.

🔖

Cite This Article

KESKİN, O., BEKTAS, M., KESKİN, C., SOYKAN, İ. (2020). A Comparison of Baseline Clinical Characteristics of Autoimmune Gastritis Patients with and without Type-1 Gastric Carcinoid Tumor. Acta Medica, Cilt: 51 - Sayı: 2, 17–24. https://ajindex.com/articles/141615

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Park JY, Lam-Himlin D, Vemulapalli R. Review of autoimmune metaplastic atrophic gastritis. Gastrointest Endosc. 2013;77(2):284-92
  2. Basuroy R, Srirajaskanthan R, Prachalias A, et al. Review article: the investigation and management of gastric neuroendocrine tumours. Aliment Pharmacol Ther. 2014;39(10):1071-84
  3. Burkitt MD, Pritchard DM. Review article: Pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther. 2006;1;24(9):1305-20 [4] Rappel S, Altendorf-Hofmann A, Stolte M. Prognosis of gastric carcinoid tumours Digestion. 1995;56(6):455-62
  4. Sato Y, Imamura H, Kaizaki Y, et al. Management and clinical outcomes of type I gastric carcinoid patients: retrospective, multicenter study in Japan. Dig Endosc. 2014;26(3):377-84 [6] Soykan I, Yakut M, Keskin O, et al. Clinical profiles, endoscopic and laboratory features and associated factors in patients with autoimmune gastritis. Digestion. 2012;86(1):20-6 [7] Tüzün A, Keskin O, Yakut M, et al. The predictive value of mean platelet volume, plateletcrit and red cell distribution width in the differentiation of autoimmune gastritis patients with and without type I gastric carcinoid tumors. Platelets. 2014;25(5):363-6
  5. Yakut M, Keskin O, Soykan I. Effect of endogenous hypergastrinemia on gallbladder volume and ejection fraction in patients with autoimmune gastritis. Hepatobiliary Pancreat Dis Int. 2012;11(5):527-31
  6. Soykan I, Yakut M, Keskin O. Hepatitis C virus antibody positivity may not be associated with hepatitis C infection in patients with autoimmune gastritis. Eur J Gastroenterol Hepatol. 2013;25(1):122-3
  7. Yakut M, Ustün Y, Kutlay S, et al. Multiparametric assessment of vascular function and atherosclerosis in patients with autoimmune gastritis: a comparative study. Dig Dis Sci. 2011;56(12):3583-9
  8. Carmel R. Prevalence of undiagnosed pernicious anemia in the elderly. Arch Intern Med 1996;156:1097-1100 [12] Song H, Held M, Sandin S, et al. Increase in the prevalence of atrophic gastritis among adults age 35 to 44 years old in Northern Sweden between1990 and 2009. Clin Gastroenterol Hepatol 2015;13(9):1592-1600 [13] Peracchi M, Gebbia C, Basilisco G, et al. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur J Endocrinol. 2005;152(3):443-8
  9. Bashir S, Gibril F, Ojeaburu JV, et al. Prospective study of the ability of histamine, serotonin or serum chromogranin A leve